S&CO Inc. Reduces Stake in Edwards Lifesciences Corp (EW)

S&CO Inc. decreased its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 8.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 5,500 shares of the medical research company’s stock after selling 500 shares during the quarter. S&CO Inc.’s holdings in Edwards Lifesciences were worth $958,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Edwards Lifesciences by 32.9% during the second quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock worth $977,456,000 after buying an additional 1,663,511 shares in the last quarter. Brown Advisory Inc. grew its holdings in shares of Edwards Lifesciences by 5.8% during the second quarter. Brown Advisory Inc. now owns 3,866,016 shares of the medical research company’s stock worth $562,775,000 after buying an additional 211,258 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Edwards Lifesciences by 5.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,147,510 shares of the medical research company’s stock worth $312,614,000 after buying an additional 107,676 shares in the last quarter. Morgan Stanley grew its holdings in shares of Edwards Lifesciences by 38.4% during the second quarter. Morgan Stanley now owns 1,329,458 shares of the medical research company’s stock worth $193,531,000 after buying an additional 369,027 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Edwards Lifesciences by 3.5% during the second quarter. Janus Henderson Group PLC now owns 1,154,249 shares of the medical research company’s stock worth $168,025,000 after buying an additional 39,390 shares in the last quarter. 82.71% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on EW shares. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Wednesday, September 26th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Guggenheim lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. SunTrust Banks boosted their price target on shares of Edwards Lifesciences to $200.00 and gave the company a “buy” rating in a research report on Friday, September 28th. Finally, Northland Securities reissued a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a research report on Thursday, October 11th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $156.79.

In other news, VP Huimin Wang sold 3,800 shares of the stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $152.79, for a total transaction of $580,602.00. Following the sale, the vice president now owns 81,665 shares of the company’s stock, valued at $12,477,595.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction dated Wednesday, October 10th. The stock was sold at an average price of $147.50, for a total transaction of $811,250.00. Following the sale, the vice president now directly owns 25,490 shares in the company, valued at approximately $3,759,775. The disclosure for this sale can be found here. Insiders sold 150,311 shares of company stock worth $21,718,936 in the last ninety days. 1.84% of the stock is currently owned by corporate insiders.

NYSE EW opened at $156.69 on Thursday. Edwards Lifesciences Corp has a 12 month low of $103.20 and a 12 month high of $175.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. The stock has a market capitalization of $31.93 billion, a price-to-earnings ratio of 41.23, a P/E/G ratio of 2.01 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The company had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. During the same quarter in the prior year, the company posted $0.84 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 10.4% compared to the same quarter last year. As a group, analysts predict that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://sportsperspectives.com/2018/11/08/sco-inc-reduces-stake-in-edwards-lifesciences-corp-ew.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply